This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Aug 27;300(8):901-2; author reply 904-6.

doi: 10.1001/jama.300.8.901-c.

Guest authorship, mortality reporting, and integrity in rofecoxib studies

Steven Ferris, Douglas Galasko, Louis Kirby

PMID: 18728256
DOI: 10.1001/jama.300.8.901-c

Comment

Guest authorship, mortality reporting, and integrity in rofecoxib studies

Steven Ferris et al. JAMA. 2008.

. 2008 Aug 27;300(8):901-2; author reply 904-6.

doi: 10.1001/jama.300.8.901-c.

Authors

Steven Ferris, Douglas Galasko, Louis Kirby

PMID: 18728256
DOI: 10.1001/jama.300.8.901-c

No abstract available

PubMed Disclaimer

Comment on

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
Ross JS, Hill KP, Egilman DS, Krumholz HM. Ross JS, et al. JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800. JAMA. 2008. PMID: 18413874
Impugning the integrity of medical science: the adverse effects of industry influence.
DeAngelis CD, Fontanarosa PB. DeAngelis CD, et al. JAMA. 2008 Apr 16;299(15):1833-5. doi: 10.1001/jama.299.15.1833. JAMA. 2008. PMID: 18413880 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems